MCID: GRW001
MIFTS: 47

Growth Hormone Secreting Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases, Genetic diseases

Aliases & Classifications for Growth Hormone Secreting Pituitary Adenoma

MalaCards integrated aliases for Growth Hormone Secreting Pituitary Adenoma:

Name: Growth Hormone Secreting Pituitary Adenoma 12 15
Somatotroph Adenoma 12 29 6
Growth Hormone-Secreting Pituitary Adenoma 44 73
Growth Hormone Producing Adenoma of the Pituitary 12
Growth Hormone Secreting Adenoma of Pituitary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6255
MeSH 44 D049912
NCIt 50 C7461
SNOMED-CT 68 254957009
UMLS 73 C0346302

Summaries for Growth Hormone Secreting Pituitary Adenoma

MalaCards based summary : Growth Hormone Secreting Pituitary Adenoma, also known as somatotroph adenoma, is related to pituitary adenoma and acromegaly. An important gene associated with Growth Hormone Secreting Pituitary Adenoma is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Octreotide and lanreotide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, skin and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have... more...

Related Diseases for Growth Hormone Secreting Pituitary Adenoma

Diseases in the Growth Hormone Secreting Pituitary Adenoma family:

Pituitary Adenoma 2, Growth Hormone-Secreting

Diseases related to Growth Hormone Secreting Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 31.5 AIP GNAS
2 acromegaly 31.0 AIP GNAS PRL SST SSTR2
3 gigantism 30.3 AIP PRL
4 mccune-albright syndrome 30.0 GNAS PRL SST
5 fibrous dysplasia 30.0 GNAS PRL SST
6 adenoma 29.7 AIP GNAS PRL SST SSTR2
7 pituitary tumors 29.1 AIP GNAS PRL SST
8 pituitary adenoma, prolactin-secreting 25.8 AIP GHSR GNAS PRKAR1A PRL SST
9 pituitary adenoma 2, growth hormone-secreting 11.4
10 pseudohypoparathyroidism, type ia 10.5 GNAS PRL
11 pituitary infarct 10.5 PRL SST
12 tsh producing pituitary tumor 10.4 PRL SST
13 chiasmal syndrome 10.4 PRL SST
14 prolactin producing pituitary tumor 10.4 PRL SST
15 villous adenoma 10.4 GNAS SST
16 nelson syndrome 10.4 PRL SST
17 type c thymoma 10.4 SST SSTR2
18 pituitary apoplexy 10.3 AIP PRL
19 carcinoid tumors, intestinal 10.3 SST SSTR2
20 pituitary hypoplasia 10.2 GHRHR PRL
21 pituitary-dependent cushing's disease 10.2 PRL SST
22 pseudopseudohypoparathyroidism 10.2 GNAS PRKAR1A
23 mixed ductal-endocrine carcinoma 10.2 SST SSTR2
24 acrodysostosis 10.2 GNAS PRKAR1A
25 endotheliitis 10.2
26 pituitary gland disease 10.1 PRL SST
27 pituitary stalk interruption syndrome 10.1 GHRHR PRL
28 albright's hereditary osteodystrophy 10.1 GNAS PRKAR1A
29 hypocalcemia, autosomal dominant 1 10.1 GNAS PRKAR1A
30 gangliocytoma 10.1
31 hyperthyroidism 10.1 GNAS PRL SST
32 pituitary carcinoma 10.0 PRL SST SSTR2
33 lentigines 9.9
34 thyroid cancer, nonmedullary, 1 9.9
35 moyamoya disease 1 9.9
36 neuroendocrine tumor 9.9
37 adenocarcinoma 9.9
38 lipomatosis 9.9
39 ganglioglioma 9.9
40 aortitis 9.9
41 thyroiditis 9.9
42 granulomatous hypophysitis 9.9
43 aneurysm 9.9
44 headache 9.9
45 pituitary adenoma 1, multiple types 9.9 AIP PRL SST
46 hyperprolactinemia 9.9 PRL SST
47 hyperpituitarism 9.9 AIP PRL SST
48 functioning pituitary adenoma 9.9 AIP PRL SST
49 endocrine organ benign neoplasm 9.9 AIP PRL SST
50 primary pigmented nodular adrenocortical disease 9.9 GNAS PRKAR1A

Graphical network of the top 20 diseases related to Growth Hormone Secreting Pituitary Adenoma:



Diseases related to Growth Hormone Secreting Pituitary Adenoma

Symptoms & Phenotypes for Growth Hormone Secreting Pituitary Adenoma

MGI Mouse Phenotypes related to Growth Hormone Secreting Pituitary Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 GHRHR SST SSTR2 GHSR GNAS PRKAR1A
2 homeostasis/metabolism MP:0005376 9.86 SST SSTR2 GHSR GNAS PRKAR1A PRL
3 endocrine/exocrine gland MP:0005379 9.72 GHRHR GNAS PRKAR1A AIP PRL
4 adipose tissue MP:0005375 9.71 GHRHR GHSR GNAS PRKAR1A
5 integument MP:0010771 9.55 GHRHR GNAS PRKAR1A AIP PRL
6 neoplasm MP:0002006 9.26 GNAS PRKAR1A AIP PRL
7 skeleton MP:0005390 9.02 SST GHRHR GHSR GNAS PRKAR1A

Drugs & Therapeutics for Growth Hormone Secreting Pituitary Adenoma

Drugs for Growth Hormone Secreting Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
2 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
3
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
4
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
5
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
6
Zinc Approved, Investigational Phase 4 7440-66-6 23994
7
Metformin Approved Phase 4 657-24-9 14219 4091
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
10 insulin Phase 4,Phase 3,Phase 2,Not Applicable
11 Mitogens Phase 4,Phase 3,Phase 2,Not Applicable
12 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Complement Factor I Phase 4,Phase 3
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Not Applicable
19 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Dopamine agonists Phase 4,Phase 3
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
22 Dopamine Agents Phase 4,Phase 3,Phase 2
23 Peripheral Nervous System Agents Phase 4,Phase 2
24 Hypoglycemic Agents Phase 4,Phase 2,Not Applicable
25 Protective Agents Phase 4,Phase 2
26 Antiparkinson Agents Phase 4,Phase 3
27 Autonomic Agents Phase 4,Phase 2
28
protease inhibitors Phase 4
29 Sitagliptin Phosphate Phase 4
30 HIV Protease Inhibitors Phase 4
31 Dipeptidyl-Peptidase IV Inhibitors Phase 4
32 Incretins Phase 4
33 Liver Extracts Phase 4
34
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
35 Carboxymethylcellulose Sodium Phase 3
36 Edotreotide Phase 3
37 Radiopharmaceuticals Phase 3
38
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
39
Dimenhydrinate Approved Phase 2 523-87-5 441281
40
Tadalafil Approved, Investigational Phase 2 171596-29-5 110635
41
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
42
Enclomiphene Investigational Phase 2 15690-57-0
43 Estrogens Phase 2,Not Applicable
44 Ethinyl estradiol, levonorgestrel drug combination Phase 2
45
Histamine Phosphate Phase 2 51-74-1 65513
46 Clomiphene Phase 2
47 Fertility Agents Phase 2
48 Chelating Agents Phase 2
49 Selective Estrogen Receptor Modulators Phase 2
50 Histamine Antagonists Phase 2

Interventional clinical trials:

(show top 50) (show all 160)
# Name Status NCT ID Phase Drugs
1 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
2 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
3 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
4 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
5 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
6 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
7 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
8 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
9 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
10 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
11 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
12 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
13 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
14 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
15 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
16 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
17 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
18 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
19 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
20 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
21 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
22 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
23 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
24 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
25 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
26 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
27 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3 Octreotide capsules
28 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
29 Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly Completed NCT00225979 Phase 3 Octreotide LAR
30 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
31 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
32 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)
33 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
34 Long Term Study With B2036-PEG Completed NCT00143416 Phase 3 Pegvisomant
35 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3 Octreotide acetate 30 mg suspension
36 Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed NCT00444873 Phase 3 lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
37 Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients Completed NCT00128232 Phase 3 Octreotide LAR
38 A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed NCT00017927 Phase 3 Pegvisomant
39 Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly Completed NCT00234572 Phase 2, Phase 3 Lanreotide (Autogel formulation)
40 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
41 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
42 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
43 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
44 Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Completed NCT00210457 Phase 3 Lanreotide (Autogel formulation)
45 Strict IGF-1 Control in Acromegaly Recruiting NCT02952885 Phase 3 Pegvisomant
46 Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Recruiting NCT02685709 Phase 3 Octreotide capsules;Injectable Somatostatin Analogs (octreotide or lanreotide);Cabergoline
47 Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Recruiting NCT03252353 Phase 3 octreotide capsules;Matching placebo
48 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
49 Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Active, not recruiting NCT02354508 Phase 3 Pasireotide LAR
50 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection

Search NIH Clinical Center for Growth Hormone Secreting Pituitary Adenoma

Cochrane evidence based reviews: growth hormone-secreting pituitary adenoma

Genetic Tests for Growth Hormone Secreting Pituitary Adenoma

Genetic tests related to Growth Hormone Secreting Pituitary Adenoma:

# Genetic test Affiliating Genes
1 Somatotroph Adenoma 29 AIP GNAS

Anatomical Context for Growth Hormone Secreting Pituitary Adenoma

MalaCards organs/tissues related to Growth Hormone Secreting Pituitary Adenoma:

41
Pituitary, Skin, Testes, Liver, Brain, Skeletal Muscle, Bone

Publications for Growth Hormone Secreting Pituitary Adenoma

Articles related to Growth Hormone Secreting Pituitary Adenoma:

(show top 50) (show all 112)
# Title Authors Year
1
Granulomatous hypophysitis caused by Rathke's cleft cyst mimicking a growth hormone-secreting pituitary adenoma. ( 28484553 )
2017
2
Surgical Outcome of Growth Hormone-Secreting Pituitary Adenoma with Empty Sella Using a New Classification. ( 28642181 )
2017
3
EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway. ( 28705113 )
2017
4
Collision tumors composed of meningioma and growth hormone-secreting pituitary adenoma in the sellar region: Case reports and a literature review. ( 29390316 )
2017
5
In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells. ( 27267119 )
2016
6
Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus. ( 26961771 )
2016
7
Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas. ( 26935389 )
2016
8
Effect of Transsphenoidal Adenectomy on Glucose Tolerance Status in Patients with Growth Hormone-secreting Pituitary Adenoma. ( 26956860 )
2016
9
Growth hormone secreting pituitary adenoma with admixed gangliocytoma and ganglioglioma. ( 27068013 )
2016
10
STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. ( 25774503 )
2015
11
Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185. ( 26036598 )
2015
12
Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. ( 25225481 )
2014
13
Change in the immunophenotype of a somatotroph adenoma resulting in gigantism. ( 25396071 )
2014
14
Treatment protocols for growth hormone-secreting pituitary adenomas combined with craniofacial fibrous dysplasia: A case report of atypical McCune-Albright syndrome. ( 25120617 )
2014
15
Gigantism caused by growth hormone secreting pituitary adenoma. ( 25077093 )
2014
16
AIP mutation identified in a patient with acromegaly caused by pituitary somatotroph adenoma with neuronal choristoma. ( 23674160 )
2013
17
Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma. ( 23728452 )
2013
18
Silencing of HEPN1 is responsible for the aggressive biological behavior of pituitary somatotroph adenomas. ( 23548416 )
2013
19
Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas. ( 23825128 )
2013
20
Silencing of RASSF3 by DNA hypermethylation is associated with tumorigenesis in somatotroph adenomas. ( 23555615 )
2013
21
Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. ( 23288882 )
2013
22
Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. ( 22585092 )
2012
23
Growth hormone secreting pituitary adenoma associated with Rathke's cleft cyst. ( 22824691 )
2012
24
Moyamoya syndrome following growth hormone-secreting pituitary adenoma. ( 22592188 )
2012
25
Neuroendocrine tumor of unknown origin metastasizing to a growth hormone-secreting pituitary adenoma. ( 22120409 )
2012
26
Ectopic growth hormone-secreting pituitary adenoma involving the clivus treated with octreotide: role of magnetic resonance imaging in the diagnosis and clinical follow-up. ( 22990736 )
2012
27
Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. ( 22659247 )
2012
28
MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. ( 21792693 )
2011
29
Spontaneous cerebrospinal fluid rhinorrhea as the initial presentation of growth hormone-secreting pituitary adenoma. ( 20888068 )
2011
30
Growth hormone- secreting pituitary adenomas: from molecular basis to treatment options in acromegaly. ( 20234189 )
2010
31
Analysis of differential gene expression by bead-based fiber-optic array in growth-hormone-secreting pituitary adenomas. ( 22993617 )
2010
32
Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. ( 19965922 )
2010
33
Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation. ( 20150876 )
2010
34
Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior ? ( 21196926 )
2010
35
Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge. ( 20067380 )
2010
36
Surgical results of growth hormone-secreting pituitary adenoma. ( 19516943 )
2009
37
Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. ( 18460561 )
2008
38
Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation. ( 19029774 )
2008
39
The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. ( 18413424 )
2008
40
Short-lasting, unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome treated successfully with transsphenoidal resection of a growth hormone-secreting pituitary adenoma. ( 18590441 )
2008
41
Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. ( 18230656 )
2008
42
Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. ( 18953743 )
2008
43
MRI finding of simultaneous coexistence of growth hormone-secreting pituitary adenoma with intracranial meningioma and carotid artery aneurysms: report of a case. ( 17334927 )
2007
44
Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess. ( 17270100 )
2007
45
Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. ( 17514647 )
2007
46
A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. ( 17411461 )
2007
47
Ectopic suprasellar growth hormone-secreting pituitary adenoma: case report. ( 17986925 )
2007
48
The evaluation of ghrelin mRNA expression in human somatotroph adenomas. ( 16648773 )
2006
49
The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. ( 16118335 )
2005
50
Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery. ( 15844307 )
2005

Variations for Growth Hormone Secreting Pituitary Adenoma

ClinVar genetic disease variations for Growth Hormone Secreting Pituitary Adenoma:

6
(show top 50) (show all 104)
# Gene Variation Type Significance SNP ID Assembly Location
1 AIP NM_003977.3(AIP): c.40C> T (p.Gln14Ter) single nucleotide variant Pathogenic rs104894194 GRCh37 Chromosome 11, 67250669: 67250669
2 AIP NM_003977.3(AIP): c.40C> T (p.Gln14Ter) single nucleotide variant Pathogenic rs104894194 GRCh38 Chromosome 11, 67483198: 67483198
3 AIP NM_003977.3(AIP): c.469-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs267606555 GRCh37 Chromosome 11, 67257508: 67257508
4 AIP NM_003977.3(AIP): c.469-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs267606555 GRCh38 Chromosome 11, 67490037: 67490037
5 AIP NM_003977.3(AIP): c.910C> T (p.Arg304Ter) single nucleotide variant Pathogenic rs104894195 GRCh37 Chromosome 11, 67258381: 67258381
6 AIP NM_003977.3(AIP): c.910C> T (p.Arg304Ter) single nucleotide variant Pathogenic rs104894195 GRCh38 Chromosome 11, 67490910: 67490910
7 AIP NM_003977.3(AIP): c.66_71delAGGAGA (p.Gly23_Glu24del) deletion Pathogenic/Likely pathogenic rs267606567 GRCh37 Chromosome 11, 67250695: 67250700
8 AIP NM_003977.3(AIP): c.66_71delAGGAGA (p.Gly23_Glu24del) deletion Pathogenic/Likely pathogenic rs267606567 GRCh38 Chromosome 11, 67483224: 67483229
9 AIP NM_003977.3(AIP): c.824dupA (p.His275Glnfs) duplication Pathogenic/Likely pathogenic rs267606580 GRCh37 Chromosome 11, 67258295: 67258295
10 AIP NM_003977.3(AIP): c.824dupA (p.His275Glnfs) duplication Pathogenic/Likely pathogenic rs267606580 GRCh38 Chromosome 11, 67490824: 67490824
11 AIP NM_003977.3(AIP): c.542delT (p.Ile182Serfs) deletion Pathogenic/Likely pathogenic rs267606559 GRCh37 Chromosome 11, 67257582: 67257582
12 AIP NM_003977.3(AIP): c.542delT (p.Ile182Serfs) deletion Pathogenic/Likely pathogenic rs267606559 GRCh38 Chromosome 11, 67490111: 67490111
13 AIP NM_003977.3(AIP): c.804C> A (p.Tyr268Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908356 GRCh37 Chromosome 11, 67258275: 67258275
14 AIP NM_003977.3(AIP): c.804C> A (p.Tyr268Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908356 GRCh38 Chromosome 11, 67490804: 67490804
15 AIP NM_003977.3(AIP): c.64C> T (p.Arg22Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908357 GRCh37 Chromosome 11, 67250693: 67250693
16 AIP NM_003977.3(AIP): c.64C> T (p.Arg22Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908357 GRCh38 Chromosome 11, 67483222: 67483222
17 AIP NM_003977.2(AIP): c.-1212_279+578del deletion Likely pathogenic GRCh37 Chromosome 11, 67249418: 67255234
18 AIP NM_003977.2(AIP): c.-1212_279+578del deletion Likely pathogenic GRCh38 Chromosome 11, 67481947: 67487763
19 AIP NM_003977.2(AIP): c.(?_1)_(*_?)del deletion Likely pathogenic
20 AIP NM_003977.3(AIP): c.100-1025_279+357del1562 deletion Likely pathogenic GRCh37 Chromosome 11, 67253452: 67255013
21 AIP NM_003977.3(AIP): c.100-1025_279+357del1562 deletion Likely pathogenic GRCh38 Chromosome 11, 67485981: 67487542
22 AIP NM_003977.3(AIP): c.138_161del24 (p.Gly47_Arg54del) deletion Likely pathogenic rs267606537 GRCh37 Chromosome 11, 67254515: 67254538
23 AIP NM_003977.3(AIP): c.138_161del24 (p.Gly47_Arg54del) deletion Likely pathogenic rs267606537 GRCh38 Chromosome 11, 67487044: 67487067
24 AIP NM_003977.3(AIP): c.166C> A (p.Arg56Ser) single nucleotide variant Likely pathogenic rs267606538 GRCh37 Chromosome 11, 67254543: 67254543
25 AIP NM_003977.3(AIP): c.166C> A (p.Arg56Ser) single nucleotide variant Likely pathogenic rs267606538 GRCh38 Chromosome 11, 67487072: 67487072
26 AIP NM_003977.3(AIP): c.241C> T (p.Arg81Ter) single nucleotide variant Pathogenic rs267606541 GRCh37 Chromosome 11, 67254618: 67254618
27 AIP NM_003977.3(AIP): c.241C> T (p.Arg81Ter) single nucleotide variant Pathogenic rs267606541 GRCh38 Chromosome 11, 67487147: 67487147
28 AIP NM_003977.3(AIP): c.244_248delGAAGG (p.Glu82Glyfs) deletion Likely pathogenic rs267606542 GRCh37 Chromosome 11, 67254621: 67254625
29 AIP NM_003977.3(AIP): c.244_248delGAAGG (p.Glu82Glyfs) deletion Likely pathogenic rs267606542 GRCh38 Chromosome 11, 67487150: 67487154
30 AIP NM_003977.3(AIP): c.249G> T (p.Gly83=) single nucleotide variant Likely pathogenic rs104895072 GRCh37 Chromosome 11, 67254626: 67254626
31 AIP NM_003977.3(AIP): c.249G> T (p.Gly83=) single nucleotide variant Likely pathogenic rs104895072 GRCh38 Chromosome 11, 67487155: 67487155
32 AIP NM_003977.3(AIP): c.250G> A (p.Glu84Lys) single nucleotide variant Likely pathogenic rs267606543 GRCh37 Chromosome 11, 67254627: 67254627
33 AIP NM_003977.3(AIP): c.250G> A (p.Glu84Lys) single nucleotide variant Likely pathogenic rs267606543 GRCh38 Chromosome 11, 67487156: 67487156
34 AIP NM_003977.3(AIP): c.280-1G> A single nucleotide variant Likely pathogenic rs267606544 GRCh37 Chromosome 11, 67256737: 67256737
35 AIP NM_003977.3(AIP): c.280-1G> A single nucleotide variant Likely pathogenic rs267606544 GRCh38 Chromosome 11, 67489266: 67489266
36 AIP NM_003977.3(AIP): c.286_287delGT (p.Val96Profs) deletion Likely pathogenic rs267606545 GRCh37 Chromosome 11, 67256744: 67256745
37 AIP NM_003977.3(AIP): c.286_287delGT (p.Val96Profs) deletion Likely pathogenic rs267606545 GRCh38 Chromosome 11, 67489273: 67489274
38 AIP NM_003977.3(AIP): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs267606546 GRCh37 Chromosome 11, 67250631: 67250631
39 AIP NM_003977.3(AIP): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs267606546 GRCh38 Chromosome 11, 67483160: 67483160
40 AIP NM_003977.3(AIP): c.308A> G (p.Lys103Arg) single nucleotide variant Likely pathogenic rs267606548 GRCh37 Chromosome 11, 67256766: 67256766
41 AIP NM_003977.3(AIP): c.308A> G (p.Lys103Arg) single nucleotide variant Likely pathogenic rs267606548 GRCh38 Chromosome 11, 67489295: 67489295
42 AIP NM_003977.3(AIP): c.350delG (p.Gly117Alafs) deletion Likely pathogenic rs267606549 GRCh37 Chromosome 11, 67256808: 67256808
43 AIP NM_003977.3(AIP): c.350delG (p.Gly117Alafs) deletion Likely pathogenic rs267606549 GRCh38 Chromosome 11, 67489337: 67489337
44 AIP NM_003977.3(AIP): c.3_4insC (p.Ala2Argfs) insertion Likely pathogenic rs267606547 GRCh37 Chromosome 11, 67250632: 67250633
45 AIP NM_003977.3(AIP): c.3_4insC (p.Ala2Argfs) insertion Likely pathogenic rs267606547 GRCh38 Chromosome 11, 67483161: 67483162
46 AIP NM_003977.3(AIP): c.404delA (p.His135Leufs) deletion Likely pathogenic rs267606551 GRCh37 Chromosome 11, 67256862: 67256862
47 AIP NM_003977.3(AIP): c.404delA (p.His135Leufs) deletion Likely pathogenic rs267606551 GRCh38 Chromosome 11, 67489391: 67489391
48 AIP NM_003977.3(AIP): c.424C> T (p.Gln142Ter) single nucleotide variant Likely pathogenic rs267606552 GRCh37 Chromosome 11, 67256882: 67256882
49 AIP NM_003977.3(AIP): c.424C> T (p.Gln142Ter) single nucleotide variant Likely pathogenic rs267606552 GRCh38 Chromosome 11, 67489411: 67489411
50 AIP NM_003977.3(AIP): c.468+1G> A single nucleotide variant Likely pathogenic rs267606554 GRCh37 Chromosome 11, 67256927: 67256927

Expression for Growth Hormone Secreting Pituitary Adenoma

Search GEO for disease gene expression data for Growth Hormone Secreting Pituitary Adenoma.

Pathways for Growth Hormone Secreting Pituitary Adenoma

GO Terms for Growth Hormone Secreting Pituitary Adenoma

Biological processes related to Growth Hormone Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.65 GHRHR PRL SST
2 G-protein coupled receptor signaling pathway GO:0007186 9.65 GHRHR GHSR GNAS SST SSTR2
3 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.52 GHRHR GNAS
4 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.51 GHRHR GNAS
5 lactation GO:0007595 9.49 GHRHR PRL
6 cellular response to glucagon stimulus GO:0071377 9.46 GNAS PRKAR1A
7 activation of adenylate cyclase activity GO:0007190 9.43 GHRHR GNAS
8 positive regulation of multicellular organism growth GO:0040018 9.4 GHRHR GHSR
9 mammary gland development GO:0030879 9.37 GHRHR PRL
10 renal water homeostasis GO:0003091 9.32 GNAS PRKAR1A
11 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.16 GHRHR GHSR
12 female pregnancy GO:0007565 9.13 GHSR GNAS PRL
13 growth hormone secretion GO:0030252 8.62 GHRHR GHSR

Molecular functions related to Growth Hormone Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.33 AIP GHSR GNAS
2 peptide hormone binding GO:0017046 8.96 GHRHR GHSR
3 growth hormone-releasing hormone receptor activity GO:0016520 8.62 GHRHR GHSR

Sources for Growth Hormone Secreting Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....